These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 17986693)

  • 1. Limited family structure and breast cancer risk.
    Iversen ES; Katki HA; Chen S; Berry DA; Parmigiani G
    JAMA; 2007 Nov; 298(17):2007; author reply 2007-8. PubMed ID: 17986693
    [No Abstract]   [Full Text] [Related]  

  • 2. Modeling genetic risk of breast cancer.
    Kauff ND; Offit K
    JAMA; 2007 Jun; 297(23):2637-9. PubMed ID: 17579233
    [No Abstract]   [Full Text] [Related]  

  • 3. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.
    King MC; Marks JH; Mandell JB;
    Science; 2003 Oct; 302(5645):643-6. PubMed ID: 14576434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer. A risky business--assessing breast cancer risk.
    Levy-Lahad E; Plon SE
    Science; 2003 Oct; 302(5645):574-5. PubMed ID: 14576407
    [No Abstract]   [Full Text] [Related]  

  • 5. Does family history predict the age at onset of new breast cancers in BRCA1 and BRCA2 mutation-positive families?
    Panchal S; Bordeleau L; Poll A; Llacuachaqui M; Shachar O; Ainsworth P; Armel S; Eisen A; Sun P; Narod SA
    Clin Genet; 2010 Mar; 77(3):273-9. PubMed ID: 20002453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective study of breast cancer risk for mutation negative women from BRCA1 or BRCA2 mutation positive families.
    Harvey SL; Milne RL; McLachlan SA; Friedlander ML; Birch KE; Weideman P; ; Goldgar D; Hopper JL; Phillips KA
    Breast Cancer Res Treat; 2011 Dec; 130(3):1057-61. PubMed ID: 21850394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
    Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
    Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contribution of BRCA1 and BRCA2 germ-line mutations to the incidence of breast cancer in young women: results from a prospective population-based study in France.
    Bonadona V; Sinilnikova OM; Chopin S; Antoniou AC; Mignotte H; Mathevet P; Brémond A; Martin A; Bobin JY; Romestaing P; Raudrant D; Rudigoz RC; Léoné M; Chauvin F; Easton DF; Lenoir GM; Lasset C
    Genes Chromosomes Cancer; 2005 Aug; 43(4):404-13. PubMed ID: 15887246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double heterozygosity for mutations in BRCA1 and BRCA2 in German breast cancer patients: implications on test strategies and clinical management.
    Heidemann S; Fischer C; Engel C; Fischer B; Harder L; Schlegelberger B; Niederacher D; Goecke TO; Doelken SC; Dikow N; Jonat W; Morlot S; Schmutzler RC; Arnold NK
    Breast Cancer Res Treat; 2012 Aug; 134(3):1229-39. PubMed ID: 22535016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study.
    Hopper JL; Southey MC; Dite GS; Jolley DJ; Giles GG; McCredie MR; Easton DF; Venter DJ
    Cancer Epidemiol Biomarkers Prev; 1999 Sep; 8(9):741-7. PubMed ID: 10498392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations.
    Gallardo M; Silva A; Rubio L; Alvarez C; Torrealba C; Salinas M; Tapia T; Faundez P; Palma L; Riccio ME; Paredes H; Rodriguez M; Cruz A; Rousseau C; King MC; Camus M; Alvarez M; Carvallo P
    Breast Cancer Res Treat; 2006 Jan; 95(1):81-7. PubMed ID: 16261400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast cancer risks for BRCA1/2 carriers.
    Wacholder S; Struewing JP; Hartge P; Greene MH; Tucker MA
    Science; 2004 Dec; 306(5705):2187-91; author reply 2187-91. PubMed ID: 15622558
    [No Abstract]   [Full Text] [Related]  

  • 13. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
    Metcalfe K; Lynch HT; Ghadirian P; Tung N; Olivotto I; Warner E; Olopade OI; Eisen A; Weber B; McLennan J; Sun P; Foulkes WD; Narod SA
    J Clin Oncol; 2004 Jun; 22(12):2328-35. PubMed ID: 15197194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer.
    Fourati A; Louchez MM; Fournier J; Gamoudi A; Rahal K; El May MV; El May A; Revillion F; Peyrat JP
    Bull Cancer; 2014 Nov; 101(11):E36-40. PubMed ID: 25418591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast Cancer Incidence After Risk-Reducing Salpingo-Oophorectomy in BRCA1 and BRCA2 Mutation Carriers.
    Fakkert IE; Mourits MJ; Jansen L; van der Kolk DM; Meijer K; Oosterwijk JC; van der Vegt B; Greuter MJ; de Bock GH
    Cancer Prev Res (Phila); 2012 Nov; 5(11):1291-7. PubMed ID: 23009828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
    Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
    JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Investigation of mutations of BRCA1 and BRCA2 genes in 52 breast cancer patients].
    Tereshchenko IV; Béshém VM; Slonimskaia EM; Ponder BA; Férokh PD; Velichko SA; Shagiakhmetova RA
    Vopr Onkol; 2002; 48(1):24-8. PubMed ID: 12101561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA1 gene mutations may explain more than 80% of excess number of ovarian cancer cases after breast cancer - a population based study from the Western Sweden Health Care region.
    Einbeigi Z; Enerbäck C; Wallgren A; Nordling M; Karlsson P
    Acta Oncol; 2010 Apr; 49(3):361-7. PubMed ID: 20151938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re: BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer.
    Friedenson B
    J Natl Cancer Inst; 2004 Aug; 96(15):1184-5; author reply 1185-6. PubMed ID: 15292392
    [No Abstract]   [Full Text] [Related]  

  • 20. [The limited spectrum of pathogenic BRCA1 and BRCA2 mutations in the French Canadian breast and breast-ovarian cancer families, a founder population of Quebec, Canada].
    Tonin PN
    Bull Cancer; 2006 Sep; 93(9):841-6. PubMed ID: 16980226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.